A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R II
Phase of Trial: Phase III
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 22 Apr 2019 Status changed from active, no longer recruiting to completed.
- 18 Oct 2018 Planned End Date changed from 4 Apr 2019 to 22 Apr 2019.
- 20 Jul 2018 Planned End Date changed from 19 Apr 2019 to 4 Apr 2019.